Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer
Part of paid clinical trials in New Haven, Connecticut.
- Sponsor
- Amgen
- Study ID
- NCT06064500
- Status
- Approved For Marketing
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Tarlatamab — DRUGTarlatamab will be administered as a 60-minute intravenous infusion with 1 mg step dose on cycle 1 day 1 followed by a 10 mg target dose on cycle 1 day 8 and cycle 1 day 15 in a 28-day cycle. Subsequent doses (10 mg) will be administered every 2 weeks.
Study Details
The primary objective of the study is to provide expanded access to and characterize the safety profile of tarlatamab in participants with advanced small cell lung cancer (SCLC) after two or more prior lines of treatment (including at least one platinum-based regimen). EA may still be available in countries outside of the United States.
Key Dates
- Status verified
- Mar 2025
Locations (9)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Yale School of Medicine | New Haven | Connecticut | 06520 | - |
| Mount Sinai Comprehensive Cancer Center | Miami Beach | Florida | 33140 | - |
| Martin Memorial Health System | Stuart | Florida | 34994 | - |
| Nebraska Cancer Specialists | Omaha | Nebraska | 68106 | - |
| Perlmutter Cancer Center at New York University Langone Hospital - 34th Street | New York | New York | 10016 | - |
| The University of North Carolina at Chapel Hill | Chapel Hill | North Carolina | 27599 | - |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | - |
| University of Virginia | Charlottesville | Virginia | 22903 | - |
| Cancer Care Northwest - South | Spokane | Washington | 99202 | - |
Find similar trials in New Haven, CT
By condition
By specialty
By research site
Yale School of Medicine· New Haven, CTMount Sinai Comprehensive Cancer Center· Miami Beach, FLMartin Memorial Health System· Stuart, FLNebraska Cancer Specialists· Omaha, NEPerlmutter Cancer Center at New York University Langone Hospital - 34th Street· New York, NYThe University of North Carolina at Chapel Hill· Chapel Hill, NC
Related Studies
- PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56PHASE1/PHASE2 · Recruiting · Memorial Sloan Kettering Cancer Center · New York, New York
- The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)PHASE1/PHASE2 · Recruiting · PMV Pharmaceuticals, Inc · Irvine, California
- Tempus Small Cell Lung Cancer Observational Study (Sculptor)Recruiting · Tempus AI · Los Alamitos, California
- Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.PHASE1/PHASE2 · Recruiting · Chipscreen Biosciences, Ltd. · Encinitas, California